Clinical trials: open to volunteers, in Philippines
Cancer
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
The rationale of the ROSY-D study is to continue to provide study treatment for patients who have participated in a parent study with Durvalumab and who are continuing to derive clinical benefit from treatment at the end of such…
- Trial name
- ROSY-D (NCT05303532)
- Testing
- Durvalumab
- Where
- 123 sites in United States, Argentina and 29 more
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Inherited Eye Disease
Clinical and Molecular Studies in Families With Inherited Eye Disease
Background: Genes are the basic units of heredity. When genes are changed, certain cells don t work like they should. Researchers want to try to better understand the genetic conditions that are linked with inherited eye…
- Trial name
- NCT02771236
- Where
- 10 sites in United States, China and 6 more
- Volunteers
- 5,000 people
- Sponsor
- National Eye Institute (NEI)
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST LTE (NCT06044337)
- Testing
- BIIB059 (litifilimab)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 306 people
- Sponsor
- Biogen
Diabetes Mellitus, Type 2
A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA).
- Trial name
- CRISTALSEA (NCT07532863)
- Testing
- No treatment given
- Where
- 6 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Cataract
JASPER™ Robotic Surgical System (Formerly Known as the ORYOM™ Robotic Surgical System) in Cataract Surgery
This is a prospective, open-label clinical study designed to evaluate the performance and safety of the JASPER™ Robotic Surgical System during cataract surgery.
- Trial name
- NCT07468409
- Testing
- JASPER™ Robotic Surgical System
- Where
- Philippines
- Volunteers
- 40 people
- Sponsor
- ForSight Robotics Ltd
Acute Myocardial Infarction
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen et al. 2018) and having additional cardiovascular risk factors.
- Trial name
- SOS-AMI (NCT04957719)
- Testing
- Selatogrel
- Where
- 821 sites in United States, Australia and 43 more
- Volunteers
- 25,000 people
- Sponsor
- Viatris Innovation GmbH
Infant Nutritional Physiological Phenomena, Infant Formula
Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants
This study will assess the effect of partially hydrolyzed, whey-based infant formulas on growth and gastrointestinal tolerance in healthy term infants.
- Conditions
- Infant Nutritional Physiological Phenomena, Infant Formula, Infant Health, Infant Development
- Trial name
- NCT05868408
- Testing
- Control Formula, Experimental Formula 1, Experimental Formula 2
- Where
- 5 sites in Philippines, Saudi Arabia
- Volunteers
- 234 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Atrial Fibrillation (AF)
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their…
- Trial name
- LILAC-TIMI 76 (NCT05712200)
- Testing
- Abelacimab
- Where
- 789 sites in United States, Argentina and 33 more
- Volunteers
- 2,500 people
- Sponsor
- Anthos Therapeutics, Inc.
Chikungunya Virus
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site…
- Trial name
- NCT07467707
- Testing
- CHIKV VLP vaccine
- Where
- 3 sites in Philippines, Thailand
- Volunteers
- 6,144 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Glycogen Storage Disease Type II, Pompe Disease
Pompe Disease Registry Protocol
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both…
- Trial name
- NCT00231400
- Where
- 272 sites in United States, Argentina and 42 more
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Neurogenic Detrusor Overactivity
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
- Trial name
- KANGUROO (NCT05491525)
- Testing
- Vibegron
- Where
- 38 sites in United States, Belgium and 14 more
- Volunteers
- 71 people
- Sponsor
- Urovant Sciences GmbH
Visual Outcome
The Purpose of This Clinical Study is to Evaluate Optimized Maximum Plus for Maximum Visual Acuity (MPMVA) Refractive Technique and Its Effect on Visual Performance.
This is a prospective, multicenter, parallel groups, non-interventional, examiner masked, comparative clinical study. Patients that participated in previous Hoya studies, and patients previous implanted with Hoya non-toric…
- Trial name
- NCT07595432
- Testing
- Non-Interventional Study
- Where
- Philippines
- Volunteers
- 140 people
- Sponsor
- Hoya Surgical Optics, Inc.
Tuberculous Meningitis
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
The purpose of this study is to compare a 6-month regimen of high-dose rifampicin (RIF), high-dose isoniazid (INH), linezolid (LZD), and pyrazinamide (PZA) versus the World Health Organization (WHO) standard of care (SOC)…
- Trial name
- NCT05383742
- Testing
- Rifampicin (RIF), Isoniazid (INH), Linezolid (LZD)
- Where
- 18 sites in Brazil, India and 10 more
- Volunteers
- 330 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Protocol RV 583 Multinational Observational Cohort of HIV and Other Infections
Multinational Observational Cohort of HIV and other Infections (MOCHI). This observational study is to gain information regarding the number of new HIV infections among people who engage in behaviors that make them vulnerable to…
- Trial name
- MOCHI (NCT05147519)
- Testing
- Novel interventions to achieve HIV remission
- Where
- 4 sites in Kenya, Nigeria and 2 more
- Volunteers
- 2,500 people
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
Cataract
Capella Scientia Development Study
This study involves collecting biometry and aberration data using the next generation biometer, Unity DX.
- Trial name
- NCT06987474
- Testing
- Unity DX and SMARTCataract DX (SCDX) Biometer, IOLMaster 700 Biometer, Argos with Alcon Image Guidance Biometer
- Where
- 4 sites in India, Philippines and 1 more
- Volunteers
- 400 people
- Sponsor
- Alcon Research
Pneumococcal Infectious Diseases
Clinical Trial of PCV13 in Infants Aged Approximately 2 Months (42 to 89 Days)
A Phase III clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in infants aged approximately 2 months (42 to 89 days).
- Trial name
- NCT07593924
- Testing
- Sinovac PCV13, Prevenar 13™
- Where
- Philippines
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Prevention, Malnutrition, Child
Evaluation of 7-day vs 1-day Packaging of Small Quantity Lipid-based Nutrition Supplementation (SQ-LNS)
Small Quantity Lipid-based Nutrient Supplements (SQ-LNS), are fortified, lipid-based nutritional supplements that were specifically designed for children 6-24 months to prevent malnutrition.
- Conditions
- Prevention, Malnutrition, Child, Nutrition
- Trial name
- NCT07540793
- Testing
- 7dp SQ-LNS, 1dp SQ-LNS
- Where
- 3 sites in Ethiopia, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- University of California, San Francisco
Tuberculosis
Rapid Research in Diagnostics Development for TB Network
To reduce the burden of TB worldwide through more accurate, faster, simpler, and less expensive diagnosis of TB Every year, more than 3 million people with TB remain undiagnosed and 1 million die.
- Trial name
- R2D2TB Network (NCT04923958)
- Testing
- Novel mycobacterial culture techniques, Novel sputum smear microscopy techniques, Sputum-based molecular assays
- Where
- 16 sites in Georgia, India and 6 more
- Volunteers
- 26,436 people
- Sponsor
- University of California, San Francisco
Pulmonary Tuberculosis
A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis
This study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB.
- Trial name
- QUANTUM-TB (NCT07209761)
- Testing
- BPaQM, BPaLM, BPaQ
- Where
- 35 sites in China, Georgia and 6 more
- Volunteers
- 532 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Immunoglobulin A Nephropathy
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
- Trial name
- NCT05248659
- Testing
- Sibeprenlimab 400 mg s.c. Q4weeks
- Where
- 158 sites in United States, Argentina and 29 more
- Volunteers
- 600 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.